A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Officials said over 71,000 Oklahomans are currently living with Alzheimer's disease. Nationally, that number is approaching 7 ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...

The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...